A Randomized, Open Label, Exploratory Trial Comparing Efficacy of Amantadine and Ropinirole in Restless Legs Syndrome

Govind Madhaw1 Ravi Gupta2,3 Puneet Dhamija4 Niraj Kumar1,2

1Department of Neurology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India 2Division of Sleep Medicine, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India 3Department of Psychiatry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India 4Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India

Address for correspondence Niraj Kumar, MD, DM, All India Institute of Medical Sciences, Neurology, Division of Sleep Medicine, Rishikesh, Uttarakhand –, India (e-mail: drnirajkumarsingh@gmail.com; niraj.neuro@aiimsrishikesh.edu.in).

Keywords
► Restless legs syndrome
► Amantadine
► Dopamine agonists
► Ropinirole
► N-Methyl-D-Aspartic acid
► Insomnia

Abstract

Objective Amantadine has both anti-glutamatergic and dopaminergic action and may improve restless legs syndrome (RLS). We compared the efficacy and adverse-effect profile of amantadine and ropinirole in RLS.

Methods In this randomized, open-label, 12-week flexible-dose exploratory study, RLS patients with international RLS study group severity scale score (IRLSS) > 10 were randomized to receive either amantadine(100-300mg/day) or ropinirole (0.5-2mg/day). Drug dose was increased until week-6 if IRLSS failed to improve by ≥10% of previous visit score. IRLSS change from baseline at week-12 was the primary outcome. Secondary outcomes included change in RLS-related quality of life (RLS-QOL) and insomnia severity index (ISI), along with clinical-global-impression of change/improvement (CGI-I), and proportion of patients with adverse-effects and resulting discontinuation.

Results Twenty-four patients received amantadine and 22 received ropinirole. Both groups had a significant effect for visit*treatment arm (F (2.19,68.15) =4.35;P = 0.01). With a similar baseline IRLSS, both intention-to-treat (ITT) and per-protocol analyses revealed comparable IRLSS until week-8, with ropinirole appearing superior from week-10 to week-12 (week-12 IRLSS, amantadine vs ropinirole:17.0 ± 5.7 vs 9.0 ± 4.4; P < 0.001). ITT analysis at week-12 showed comparable proportion of responders (≥10% IRLSS reduction) in both groups (P = 0.10). Both drugs improved sleep and QOL, but week-12 scores favoured ropinirole [(ISI:14.4 ± 5.7 vs 9.4 ± 4.5; P = 0.001) ;(RLS-QOL:70.4 ± 17.9 vs 86.5 ± 9.8; P = 0.005)]. CGI-I at week-12 favoured ropinirole (Mann-Whitney U = 35.50, S. E = 23.05;P = 0.01). Four patients in amantadine and...
Introduction

Restless legs syndrome (RLS) is a common neurological disorder characterized by an urge to move legs accompanied by abnormal sensations deep inside the muscles, occurring at rest, especially in evening, and alleviated by movement of the affected limb(s).\(^1\) RLS may affect all ages. Its prevalence ranges from 5–15% in general population, with females being more commonly affected.\(^2,3\) As compared to West, the prevalence is lower in Indian population (2-3%).\(^4,5\) Although unclear, the pathophysiology of RLS appears to include a disruption in dopaminergic neurotransmission in patients having genetic predisposition to RLS, apparently precipitated in the presence of environmental and co-morbid disorders.\(^6\) Functional deficiency of dopamine in basal ganglia and iron deficiency in central nervous system are thought to play a role in its pathophysiology.\(^7\) In addition, hypersensitivity of cortico-striatal glutamatergic pathways and higher basal glutamate levels in thalamic neurons have also been reported in patients with RLS.\(^8\)

Several pharmacological and non-pharmacological treatments have been studied for RLS. First-line pharmacological treatments of RLS include dopaminergic agents including ropinirole, pramipexole, rotigotine and alpha 2 delta (α2δ) ligands such as gabapentin enacarbil and pregabalin.\(^9\) Although dopamine agonists and α2δ ligands have proven efficacy in RLS, at least in short term, they may have bothersome adverse-effects viz., impulsivity, weight gain and depression.\(^7\) In addition, appearance of augmentation with dopaminergic agents further compounds the problem, which has been reported in one-fifth of RLS patients and occurs in 8% patients per year.\(^10\) These issues warrant exploration of pharmacological agents that are at least equi-efficacious and safer for RLS management.

Amantadine, a weak N-Methyl-D-Aspartic acid (NMDA) antagonist which increases release of dopamine and prevents its reuptake, has proven safety and efficacy in Parkinson’s disease.\(^11\) In addition, its anti-glutamatergic effect may also negatively modulate the cortico-striatal hypersensitivity and heightened glutamate activity in thalamus.\(^12\) It is also not known to have adverse-effects associated with other dopaminergic medications described above. Because of these properties, it may improve RLS without having major adverse effects. However, to date only one open label study is available which shows that it may improve RLS.\(^13\)

We hypothesized that amantadine would have efficacy equivalent to ropinirole, but a safer adverse effect profile compared to ropinirole. Hence, this comparative exploratory study was planned to compare efficacy and adverse effect profile of amantadine and ropinirole among patients having RLS.

Material and Methods

This randomized, open-label, 12-week flexible dose, exploratory trial was registered (Trial ID REF/2019/04/025566, CTRI/2020/11/029296) and approval from institutional ethics committee was obtained. Considering the large placebo response among patients with RLS,\(^14\) an equivalence margin of < 35% difference in response rate during the course of trial was defined for accepting two drugs to be equal (available at https://www.sealedenvelope.com/power/binary-equivalence/).\(^15\) Clinically significant response rate (≥ 10% decrease in IRLS score) in treatment groups was assumed to be 90%. Fifteen patients were required in each group to give a power of 90% and alpha value of 5% for equivalence trial. A sample size of 15 completed patients in each group (30 in total) was found appropriate for this study, with an allocation ratio of 1:1.\(^16,17\) The expected dropout rate was 10-15% in each arm. However, polysomnography had to be removed from the trial in view of sleep laboratory being closed due to coronavirus disease-19 (COVID-19) pandemic.

All patients, > 18 and < 60 years age, visiting Sleep Disorders Clinic and Movement Disorders Clinic from February 2020 to February 2021 were screened for RLS using International RLS study group criteria,\(^1\) by two authors (RG and NK) experienced in diagnosis and management of RLS. RLS diagnosis was based on face-to-face interview along with clinical examination. Patients symptomatic for at least 6 months at the time of screening, with RLS symptoms occurring ≥ 15 nights per month, were requested to participate. However, patients were excluded if they were meeting any of the following criteria- patients using non-pharmaceutical measures for management of RLS (e.g., sequential compression devices), having symptomatic neuropathies or current diagnosis of clinically relevant comorbid conditions that may confound clinical assessments of RLS and/or severe enough to disturb sleep; Pregnant women; had neurodegenerative diseases that interfered with interview; using medications that were likely to influence sleep architecture or interacting with dopaminergic system e.g., dopaminergic agents, sedatives, hypnotics, antipsychotics, cannabis, opioids, opiates; had low Glomerular filtration rate (calculated by formula- eGFR < 60ml/min/1.73m\(^2\) body surface area); Hemoglobin < 10gm/dl; and if they had known hypersensitivity to any components of the trial medication or similar drugs.
Eligible patients were explained the rationale of the study. Consecutive patients providing written informed consent and having IRLS score $> 10$, with/without any medication for treatment of RLS, were included. Patients on any medication for RLS symptoms were given a wash-out period of 4 weeks. Severity of RLS at the time of starting the trial medication was considered as the baseline IRLS score.

The primary end point was change in IRLS score from baseline following initiation of therapy at week 12. The secondary endpoints included change in RLS related quality of life, severity of insomnia and overall clinical impression of change/improvement from baseline at week 12. In addition, adverse events related to the therapies were recorded.

**Assessments**

International RLS study group severity rating scale (IRLS) was used to assess severity of RLS among RLS patients was assessed using RLS Quality of Life (RLS-QOL) scale, and Insomnia severity index (ISI) was used to assess the presence and/or severity of insomnia symptoms. Clinical global impression/Improvement/change (CGI-I) scale was used to assess global improvement. Permission was obtained from the relevant agencies for using these questionnaires. While IRLS score was assessed every two weeks (week 0, 2, 4, 6, 8, 10, and 12), ISI and RLS-QOL were assessed at baseline and end of week 12. CGI-I scale was used to assess the improvement in clinical condition at week 12.

Assessment of patients was done in outpatient department at baseline and at week 12 visit. For other visits, patients were given the flexibility to contact treating team either through tele-medicine services or physically in the outpatient department. However, they were encouraged to attend the outpatient services whenever possible.

**International RLS Study Group Rating Scale (IRLS)**

Developed by International RLS Study group (IRLSSG) in 2003, IRLS assess and quantify the RLS symptoms during past one week. It is a 10-item scale, and each item is scored on a 4 point Likert’s scale (0 – absence of the symptom, 4 – very severe symptom). This scale classifies severity of RLS on a score ranging between 0-40 and indicates the frequency and severity of RLS symptoms and their impact on sleep, mood, and activities of daily living. Score up to 10 are considered mild, between 11 to 20 as moderate, 21 to 30 as severe, and 31 to 40 as very severe RLS. Validated Hindi version of IRLS having high internal consistency (Cronbach’s Alpha 0.86) was used in this study.

**Insomnia Severity Index (ISI)**

It’s a patient reported measure which assesses presence and/or severity of insomnia during past seven days. Score ranges between 0-28. Score below 7 is considered clinically insignificant insomnia, 8-14- mild, 15-21 moderate and 22-28 as severe insomnia. It’s validated Hindi version was used (Cronbach’s Alpha of 0.91).

**RLS Quality of Life (RLS-QOL)**

RLS-QoL is an 18-item scale to assess the impact of RLS on daily life in several domains ranging from professional, emotional, and social. Higher score of RLS-QoL indicate a better quality of life. It has a high internal consistency (Cronbach’s alpha 0.92) and acceptable test-retest reliability (interclass correlation coefficient 0.84). For Hindi speaking patients, a validated Hindi questionnaire was used (Cronbach’s alpha 0.85).

**Clinical Global Impression-Improvement/change (CGI)**

CGI offers a brief and practical measurement tool which can be easily administered by a clinician. It is a three-item clinician-rated scale, that measures illness severity (CGI-S), global improvement or change (CGI-I) and therapeutic response. In this study, CGI-I part of the scale was used, which has scores ranging from 1 (very much improved) through to 7 (very much worse).

**Adverse Effects**

At each visit, patients were asked regarding any problem, other than those related to RLS, after starting the new drugs in the trial, since the last visit. Proportion of patients developing adverse effects and resulting discontinuation were assessed.

**Intervention**

Patients were randomly assigned to receive amantadine (100-300 mg PO flexible dose) and ropinirole (0.5-2mg PO flexible dose), once daily, 1-3 hours before bedtime. Simple randomization was done using a computer-generated randomization list. This list was kept securely with the author (PD) who was not involved in the clinical assessment of patients, and he assigned the patients to one of the treatment arms. Assignment to groups was disclosed for one patient at a time.

Amantadine was started at the dose of 100 mg per day. Dose was increased by 100mg every two weeks up to a maximum of 300 mg per day, if the IRLS score failed to improve by at least 10% of the previous visit score. Patients in ropinirole arm were started with 0.5 mg per day with followed by an increase of 0.5mg every two weeks until the maximum daily dose of 2 mg, if the IRLS score failed to improve by at least 10% of previous visit score. If there was inability to tolerate a higher dose, it was reduced to the previous level. Dose adjustments were allowed only for the first six weeks and thereafter the patients were maintained on a stable dose for the next six weeks.

Patients who were lost to follow up or developed serious adverse effects (not relieved with time or dose reduction) and those non-compliant to therapy were discontinued. For each dropout, a new patient was included so as to complete 15 patients in each arm. Adverse events from treatment were monitored throughout the trial.

**Statistical Analysis**

The analysis was done using Statistical Package for Social Sciences (SPSS) v 28.0 (IBM Corp. Released 2021. IBM SPSS Statistics for Mac, Version 28.0.1.0 (142) Armonk, NY: IBM Corp.) Analysis was done using two methods - per protocol
and intention to treat (ITT) using last observation carried forward method for imputation. Patients completing follow-up and assessments at least up to 6 week following initiation of the therapy were included in ITT analysis. Descriptive statistics was calculated. Normality of data was tested using Shapiro-wilk test. Chi Square test was used to compare categorical variables across groups. To compare continuous variables across groups that were normally distributed, paired t test and independent sample t test were applied. Man-Whitney U test was done to compare continuous variables not having normal distribution (CGI-I).

A mixed ANOVA with Bonferroni correction was used to compare improvement in IRLS score over the study period. Age, duration of illness, family history of illness and serum ferritin at baseline were taken as co-variates. While comparing the change in RLS severity across seven timepoints of measurements, test of sphericity could not be met in the sample; hence Greenhouse-Geiser corrected degrees of freedom were used while interpreting the results. Levene’s test depicted a homogenous variance.

Results

A total of 77 patients fulfilling the diagnostic criteria for RLS were screened for inclusion in IRLS score over the study period. Age, duration of illness, family history of illness and serum ferritin at baseline were taken as co-variates. While comparing the change in RLS severity across seven timepoints of measurements, test of sphericity could not be met in the sample; hence Greenhouse-Geiser corrected degrees of freedom were used while interpreting the results. Levene’s test depicted a homogenous variance.

A total of 77 patients fulfilling the diagnostic criteria for RLS were screened for inclusion in the trial, out of which 31 were excluded and 46 underwent randomization. Thirty-seven patients completed week 6 follow-up, 19 in the amantadine and 18 in the ropinirole group and were included in ITT analysis (Fig. 1). Data obtained in this study were normally distributed except for CGI-I. (Supplementary Table S1). Trial ended after 15 patients in each group completed the week 12 follow-up and these patients were included in per-protocol analysis.

Baseline characteristics of patients in amantadine and ropinirole groups were comparable, irrespective of ITT or per-protocol analysis (Table 1). The most common words used to describe the RLS symptoms were pain (43.5%, 20), restlessness (23.9%, 11), unpleasant sensation (15.2%, 7), stiffness (10.9%, 5), and insect-crawling like sensation (8.7%, 4). Twenty-nine (63.04%) patients never received any drug for their RLS symptoms. Patients already on medication for RLS were comparable in between both arms (Supplementary Table S2). While ropinirole was used by three patients in the past, none had taken amantadine.

After 6 weeks of treatment, patients in ITT analysis were either on amantadine monotherapy (mean [SD] = 210.52 [65.78] mg per day; range 100–300 mg per day) or ropinirole (mean [SD] = 0.97 [0.46] mg per day; range 0.5–2 mg per day).

As per ITT analysis at 12 weeks, proportion of responders (≥ 10% reduction in IRLS score) in both the groups was comparable (P = 0.10) (Figure 2). A mixed ANOVA was applied to compare the change in IRLS score across visits between the two treatment groups (Figure 3; Supplementary Table S3; Supplementary Table S4). Mauchly’s test of sphericity was violated in both ITT and per-protocol analysis. Hence, Greenhouse-Geiser values were considered. On ITT analysis, a significant effect for visit×treatment arm (F (2.19, 68.15) = 4.35; P = 0.01) was observed. A significant effect of “treatment arm,” (F (1, 31) = 10.12; P = 0.003) and “duration of illness,” (F(1, 31) = 5.28; P = 0.02) was observed in “between the patients”

Fig. 1 CONSORT flowchart for screening, inclusion, and dropout.
comparison. However, no effect was observed for visit’age, visit’duration of illness, visit’family history, and visit’ferritin. Similar results were obtained using per-protocol analysis (► Figure 3; ► Supplementary Table S3; ► Supplementary Table S5) where a significant mean effect for visit’treatment arm, \( F(2.36, 56.69) = 5.25; P = 0.005 \) in “within the patients” comparison and for “treatment arm,” \( F(1, 24) = 5.80; P = 0.02 \) and “duration of illness,” \( F(1, 24) = 4.50; P = 0.04 \) in “between the patients” comparisons was observed. However, no effect was observed of visit’age, visit’duration of illness, visit’family history, and visit’ferritin.

Improvement in IRLS appeared within first 2 week with both the drugs. The IRLS score showed a progressive improvement over the 12-week period in patients on ropinirole, but it stabilized after week 6 in the amantadine group. ► Figure 3 shows that the confidence intervals of mean IRLS scores in both groups are overlapping until visit 5 i.e., week 8 follow-up. Thereafter, compared to the amantadine group, patients in the ropinirole group had a significantly lower IRLS score from week 10 to week 12 in both ITT and per-protocol analyses (► Figure 3; ► Supplementary Table S3). Sleep disturbance and RLS related quality of life were comparable at the baseline between two groups, however, it improved significantly in both groups by week 12, with greater improvement in ropinirole arm (► Table 2). CGI-I at week 12 favoured ropinirole (Mann-Whitney U = 35.50, S. E = 23.05; P = 0.01).

Adverse effects were reported by two patients (9.1%) in ropinirole group, and four (16.7%) in amantadine group. Two of these four patients in the amantadine group chose to

---

### Table 1 Baseline demographic and clinical parameters of patients included in the trial.

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Parameters</th>
<th>Intention to treat</th>
<th>Per protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Amantadine arm (n = 19)</td>
<td>Ropinirole arm (n = 18)</td>
</tr>
<tr>
<td>1</td>
<td>Age in years: mean (SD)</td>
<td>40.3 (12.4)</td>
<td>40.6 (11.6)</td>
</tr>
<tr>
<td>2</td>
<td>Gender (Female): n (%)</td>
<td>13 (68.4%)</td>
<td>12 (66.7%)</td>
</tr>
<tr>
<td>3</td>
<td>Disease duration in years: mean (SD)</td>
<td>3.4 (2.2)</td>
<td>4.6 (3.1)</td>
</tr>
<tr>
<td>4</td>
<td>Delay in Diagnosis in years: mean (SD)</td>
<td>3.2 (2.1)</td>
<td>4.2 (3.0)</td>
</tr>
<tr>
<td>5</td>
<td>Chronic persistent RLS: n (%)</td>
<td>13 (68.4%)</td>
<td>13 (72.2%)</td>
</tr>
<tr>
<td>6</td>
<td>Associated restless Arms: n (%)</td>
<td>9 (47.4%)</td>
<td>6 (33.3%)</td>
</tr>
<tr>
<td>7</td>
<td>Family history of RLS: n (%)</td>
<td>8 (42.1%)</td>
<td>5 (27.8%)</td>
</tr>
<tr>
<td>8</td>
<td>Associated comorbidities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>Hypertension: n (%)</td>
<td>5 (26.3%)</td>
<td>2 (11.1%)</td>
</tr>
<tr>
<td>B</td>
<td>Diabetes mellitus: n (%)</td>
<td>3 (15.8%)</td>
<td>2 (11.1%)</td>
</tr>
<tr>
<td>C</td>
<td>Migraine: n (%)</td>
<td>6 (31.6%)</td>
<td>7 (38.9%)</td>
</tr>
<tr>
<td>D</td>
<td>Hypothyroid: n (%)</td>
<td>3 (15.8%)</td>
<td>2 (11.1%)</td>
</tr>
<tr>
<td>9</td>
<td>RLS and sleep scores</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>IRLS score at baseline: mean (SD)</td>
<td>23.4 (5.1)</td>
<td>22.4 (7.8)</td>
</tr>
<tr>
<td>B</td>
<td>RLS-QOL at baseline: mean (SD)</td>
<td>59.6 (17.8)</td>
<td>58.8 (23.6)</td>
</tr>
<tr>
<td>C</td>
<td>ISI at baseline: mean (SD)</td>
<td>18.7 (5.0)</td>
<td>19.5 (6.5)</td>
</tr>
<tr>
<td>10</td>
<td>Severity of RLS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>Moderate RLS</td>
<td>5 (26.3%)</td>
<td>8 (44.4%)</td>
</tr>
<tr>
<td>B</td>
<td>Severe RLS</td>
<td>13 (68.4%)</td>
<td>6 (33.3%)</td>
</tr>
<tr>
<td>C</td>
<td>Very severe RLS</td>
<td>1 (5.3%)</td>
<td>4 (22.2%)</td>
</tr>
<tr>
<td>11</td>
<td>Hemoglobin (gm%): mean (SD)</td>
<td>11.4 (1.7)</td>
<td>11.8 (1.7)</td>
</tr>
<tr>
<td>12</td>
<td>Serum Iron (mcg%): mean (SD)</td>
<td>75.8 (31.3)</td>
<td>67.7 (29.6)</td>
</tr>
<tr>
<td>13</td>
<td>Serum ferritin (ng/ml): mean (SD)</td>
<td>126.9 (57.4)</td>
<td>135.9 (65.9)</td>
</tr>
</tbody>
</table>

Abbreviations: IRLS score: International restless legs syndrome severity score; ISI: insomnia severity index; RLS-QOL: RLS quality of life scale; RLS: restless legs syndrome; SD: standard deviation.

Chi-Square test was used to compare categorical variables across groups. Continuous variables across groups were normally distributed and compared using independent sample t test.

None of the patients in either group had low serum iron or ferritin levels requiring an iron supplement.
discontinue amantadine before week 6. One had blurring of vision, and the other developed recurrent vomiting and blurring of vision. The other two patients had constipation and dizziness respectively, however, these adverse effects were mild and resolved over time. In ropinirole arm, diarrhoea and perioral paraesthesia were reported by two patients, however, they were mild and transient.

Discussion

This study showed that in middle-aged patients having moderate to severe RLS, a 12-week therapy with either amantadine or ropinirole reduces the severity of RLS symptoms. For both the drugs, the improvement in IRLS score appeared within first 2 weeks. While the improvement in IRLS score continued through the 12-week period in ropinirole group, it stabilized after week 6 in patients on amantadine. As compared to amantadine group, patients in ropinirole group had a significantly lower IRLS score from week 10 to week 12. Results remained unaffected by either method of analysis, ITT as well as per protocol. In addition, an improvement in sleep and quality of life was observed with both drugs, with a greater improvement in the ropinirole group. CGI-I at week 12 favoured ropinirole. A higher proportion of patients in the amantadine group developed adverse effects.

Ropinirole, a non-ergot dopaminergic agonist, has US Food and Drug Administration (FDA) approval for use in RLS. Based on several randomized controlled trials, a task force commissioned by the International Parkinson and Movement Disorder Society (2017), has reported ropinirole (0.78–4.6 mg/ day) to be efficacious in RLS. Results of the present study are in concordance with earlier findings. However, previous trials of ropinirole included European and American population which might be genetically different from the Indian population studied in the present trial. Additionally, patients in these studies were older, had longer duration of illness compared to present study, and studies adopted different methodologies making direct comparison difficult. In addition to its comparison with placebo, ropinirole has been compared with other drugs including gabapentin and bupropion, but never with amantadine.

To date only one single-arm prospective open-label study, involving 21 patients, reported improvement in RLS symptoms with amantadine, used in a flexible dose of 100 - 300 mg/day. While the mean dose of amantadine was 227 mg/day in the previous study, it was 210.52 mg/day in present study. A number of factors could be responsible for difference in doses viz., older age of patients (average age 70 ± 9 years compared to 40.3 ± 12.4 years in the present study), longer duration of illness (average duration 18 ± 17 years compared to 3.4 ± 2.2 years in the present study), non-improvement with the management of RLS (57% in previous trial compared to 36.9% in present study), presence of peripheral polyneuropathy (38% in previous trial compared to none in present study), and timed dose escalation (every 3-5 days) compared to escalation based on change in IRLS score in present study.

Present study differs from that by Evidente et al. in several ways other than mentioned above– first, RLS severity in the present trial was assessed using a validated questionnaire, absence of concomitant medications, scheduled assessment points during the study, which add to the reliability of the results. However, the present study shows benefit from the amantadine for 3 months, while Evidente et al reported persistent benefit for up to 13 months (mean, 3.6 ± 4.5 months) in nearly half of their 21 patients without augmentation and rebound. Duration of present study is too short to comment on augmentation. The adverse effects encountered in present study have been previously reported. Ropinirole was better tolerated than amantadine throughout the study period.

![Fig. 2](image-url) Proportion of patients having international restless legs syndrome study group severity score reduction ≥ 10% from baseline at 12 weeks.
We hypothesized that amantadine would bring greater improvement in RLS compared to ropinirole as amantadine had two pronged action, anti-glutamate as well as dopaminergic facilitation, compared to ropinirole which is traditionally believed to activate only the post-synaptic dopamine D2 receptors. However, this study showed while both were found to be efficacious in reducing RLS severity as well as improving sleep and quality of life, ropinirole was significantly superior to amantadine. As compared to amantadine group, patients in ropinirole group had a significantly lower IRLS score from week 10 to week 12. Recent advancement in pathophysiology of RLS have shown that it is a state of

![Graphical representation of effect of amantadine and ropinirole on International restless legs syndrome study group rating scale (IRLS) score at different timepoints in amantadine and ropinirole arm using (A) intention to treat and (B) per-protocol analysis. Please refer to Supplementary Table S3 for details regarding IRLS score at different timepoints.](image-url)
presynaptic dopamine excess, with increased synthesis and release of dopamine that contribute to akathisia, and hyper-glutamatergic along with hyper-adenosinergic state leading to arousal part. In addition, work on animal models of RLS suggested a possible anti-glutamatergic role of ropinirole, in addition to its dopaminergic modulation action. The weak anti-glutamatergic effect of amantadine, related to its low-affinity and non-competitive NMDA-receptor antagonism, appears a plausible reason for earlier plateau in its effect.

In addition to RLS, amantadine also improved insomnia. This may be ascribed to the anticholinergic effect of amantadine. Improvement in quality-of-life scores may be because of its antidepressant, mood-elevating, attention-improving, anti-fatigue, and sexual function improving properties. Amantadine has also been shown to facilitate the action of dopaminergic agents. This raises a possibility of its role as an adjuvant to the mainstream dopamine therapy among partial responders that should be investigated in future.

Like any other scientific investigation, present study also has some limitations. First, sample size was small and study period was short. Second, although randomized, our study was open label. Third, as compared to other reported studies, patients were younger and had a shorter disease duration. Fourth, there was no placebo arm in this study. Lastly, dose of amantadine could have been increased further. Future studies using higher doses of amantadine or using it in combination with dopamine agonists may advance our understanding of its use in RLS.

**Conclusions**

The present study reports equivalent improvement in RLS symptoms in middle-aged patients having moderate to severe RLS using either amantadine or ropinirole for 8 weeks. However, from week 10 to week 12, ropinirole appeared superior in efficacy for reducing the RLS symptoms. Ropinirole was better tolerated than amantadine throughout the study. Though amantadine shows an efficacy similar to ropinirole in reducing RLS symptoms in short-term, yet its tolerability remains a concern.

**Conflict of Interest**
None declared.

**Acknowledgement**
Authors would like to thank the patients and their family members.

**References**


---

**Table 2** Comparison of sleep and quality of life within and across groups (Per protocol analysis).

<table>
<thead>
<tr>
<th>Scores and timelines</th>
<th>Amantadine arm (n = 15)</th>
<th>Ropinirole arm (n = 15)</th>
<th>P** value</th>
<th>Cohen’s d (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ISI score: mean (SD)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At week 0</td>
<td>19.4 (5.3)</td>
<td>20.9 (5.0)</td>
<td>0.42</td>
<td>–</td>
</tr>
<tr>
<td>At week 12</td>
<td>14.4 (5.7)</td>
<td>9.4 (4.5)</td>
<td>0.01</td>
<td>0.98 (0.21 to 1.73)</td>
</tr>
<tr>
<td>P-value*</td>
<td>0.004</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cohen’s d (95% CI)</td>
<td>0.88 (0.27 to 1.47)</td>
<td>2.62 (1.53 to 3.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RLS-QOL score: mean (SD)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At week 0</td>
<td>58.1 (19.5)</td>
<td>55.9 (23.8)</td>
<td>0.77</td>
<td>–</td>
</tr>
<tr>
<td>At 12 weeks</td>
<td>70.4 (17.9)</td>
<td>86.5 (9.8)</td>
<td>0.005</td>
<td>-1.11 (-1.87 to -0.33)</td>
</tr>
<tr>
<td>P-value*</td>
<td>0.009</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cohen’s d (95% CI)</td>
<td>-0.784 (-1.35 to -0.19)</td>
<td>-1.57 (-2.33 to -0.79)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CI: Confidence interval; ISI: Insomnia severity index, RLS-QOL: Restless Legs Syndrome - Quality of life score.  
P*: Paired sample test.  
P**: Independent sample test.
Comparing amantadine and ropinirole in RLS


26 Trenkwalder C, Garcia-Borreguero D, Montagna P, et al; Therapy with Ropinirole; Efficacy and Tolerability in RLS 1 Study Group. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75(01):92–97


